2018 Advances for Practitioners

5 (4 votes)

Recorded On: 11/12/2018

This program reviews the most recent advances in the clinical management of patients with cirrhosis. Topics of discussion include the use of beta blockers, anticoagulants and albumin for managing different complications of cirrhosis. Additionally, the most updated recommendations regarding  screening issues for patients with cirrhosis will be reviewed.

Michael B. Fallon

Juan G. Abraldes

Dr. Juan G. Abraldes is a Transplant Hepatologist, Professor and Director of the Liver Unit at the University of Alberta, Edmonton, Canada. He gained his MD in 1995 from the University of Santiago de Compostela, Spain, and got his Board Certificate in Gastroenterology and Hepatology at the Liver Unit, Hospital Clinic, University of Barcelona (2000). He did a postdoctoral training at Yale University (2003–2004). He was a faculty member of the Liver Unit, at Hospital Clinic Barcelona, until 2013, when he moved to the University of Alberta.

He has published more than 200 papers on the pathophysiology, diagnosis and management of end-stage liver disease. He has co-authored the international Baveno guidelines for the management of portal hypertension in 2005, 2010 and 2015. He is the co-author of the American Association for the Liver Clinical Guidance for the management of varices and variceal bleeding in cirrhosis and was the chair of the AASLD Special Interest Group in Portal Hypertension between 2017 and 2018.

Guadalupe Garcia-Tsao

Dr. Garcia-Tsao is Professor of Medicine, Chief of Digestive Diseases and Program Director of the Hepatitis C Resource Center at Veteran’s Administration-Connecticut Healthcare System, as well as Director of Clinical and Translational Core at Yale Liver Center. She is a past president of AASLD. She received her M.D. and training at Universidad Nacional Autónoma de Mexico. Her primary research focus is on clinical research which focuses on cirrhosis and its complications, and she also is involved in the study of bacterial infections in cirrhosis, a complication that is often overlooked.

Nicolas M. Intagliata

Key:

Complete
Failed
Available
Locked
Screening Issues in Cirrhosis
Open to view video.
Open to view video. Presenter: Michael Fallon
Use of Non-Selective Beta-Blockers in Cirrhosis
Open to view video.
Open to view video. Presenter: Juan Abraldes
Use of Albumin in Cirrhosis
Open to view video.
Open to view video. Presenter: Guadalupe Garcia-Tsao
Anticoagulation in Cirrhosis
Open to view video.
Open to view video. Presenter: Nicolas Intagliata
Final Evaluation
Final Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.